Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03825796
Title CPX-351 Plus Enasidenib for Relapsed AML
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

CPX-351 + Enasidenib

Cytarabine + Enasidenib

Enasidenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA / Jonsson Comprehensive Cancer Center Los Angeles California 90095 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
University of California San Diego San Diego California 92103 United States Details
University of California San Francisco San Francisco California 94143 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field